Clinical procedure Before trial inclusion patients were routinely assessed in the GU clinic, that is clinical examination of the AG tract including proctoscopy, and vaginal speculum in women, rectal, urethral, cervical, and vaginal swabs as appropriate to exclude non specific urethritis (NSU) (diagnosed in males by > 10 pus cells on a Gram stained anterior urethral swab and a negative culture for N Gonorrhoeae (GC), non specific genital infection (NSGI) (diagnosed in (1) female sexual partners ofmales with NSU (2) females with a positive cervical Microtak for Chlamydia trachomatis), infections with N Gonorrhoeae (GC), Gardnerella vaginalis (GV), Trichomonas vaginalis (TV), candida, and a blood sample for syphilis serology. In addition females had colposcopy examination, with biopsy of any abnormal representative areas, and pap smear for cervical cytology. Any other infections detected were appropriately treated before trial entry.
According to treatment group allocation, patients were given subcutaneous IFN alpha 2a, in doses of three million units, or placebo (normal saline), on three separate days in the first week. Thereafter patients had IFN, three million units, or placebo injections, twice weekly, and cryotherapy of AG warts once a week, for the following 6 weeks; a total of 7 weeks treatment in all. Cervical warts/subclinical preneoplasias were not specifically treated.
The study was observer blind. Injections of IFN or placebo were administered by a research nurse (HL), and cryotherapy, clinical and colposcopic assessments were performed independently by one observer (JH). At initial assessment and the 8 week review, patients answered a standardised questionnaire, had an AG tract examination including proctoscopy (application of dilute acetic acid to the external AG regions was not performed), cervical pap smear, and colposcopy examination. At the 3 month review patients had repeat AG tract examina- 
